Literature DB >> 24407029

Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice.

Bernd Hewing1, Saj Parathath, Tessa Barrett, Wing Ki Kellie Chung, Yaritzy M Astudillo, Tadateru Hamada, Bhama Ramkhelawon, Thomas C Tallant, Mohamed Shaif S Yusufishaq, Joseph A Didonato, Ying Huang, Jennifer Buffa, Stela Z Berisha, Jonathan D Smith, Stanley L Hazen, Edward A Fisher.   

Abstract

OBJECTIVE: Preclinical and clinical studies have shown beneficial effects of infusions of apolipoprotein A-I (ApoA-I) on atherosclerosis. ApoA-I is also a target for myeloperoxidase-mediated oxidation, leading in vitro to a loss of its ability to promote ATP-binding cassette transporter A1-dependent macrophage cholesterol efflux. Therefore, we hypothesized that myeloperoxidase-mediated ApoA-I oxidation would impair its promotion of reverse cholesterol transport in vivo and the beneficial effects on atherosclerotic plaques. APPROACH AND
RESULTS: ApoA-I(-/-) or apolipoprotein E-deficient mice were subcutaneously injected with native human ApoA-I, oxidized human ApoA-I (myeloperoxidase/hydrogen peroxide/chloride treated), or carrier. Although early postinjection (8 hours) levels of total ApoA-I in plasma were similar for native versus oxidized human ApoA-I, native ApoA-I primarily resided within the high-density lipoprotein fraction, whereas the majority of oxidized human ApoA-I was highly cross-linked and not high-density lipoprotein particle associated, consistent with impaired ATP-binding cassette transporter A1 interaction. In ApoA-I(-/-) mice, ApoA-I oxidation significantly impaired reverse cholesterol transport in vivo. In advanced aortic root atherosclerotic plaques of apolipoprotein E-deficient mice, native ApoA-I injections led to significant decreases in lipid content, macrophage number, and an increase in collagen content; in contrast, oxidized human ApoA-I failed to mediate these changes. The decrease in plaque macrophages with native ApoA-I was accompanied by significant induction of their chemokine receptor CCR7. Furthermore, only native ApoA-I injections led to a significant reduction of inflammatory M1 and increase in anti-inflammatory M2 macrophage markers in the plaques.
CONCLUSIONS: Myeloperoxidase-mediated oxidation renders ApoA-I dysfunctional and unable to (1) promote reverse cholesterol transport, (2) mediate beneficial changes in the composition of atherosclerotic plaques, and (3) pacify the inflammatory status of plaque macrophages.

Entities:  

Keywords:  apolipoprotein A-I; atherosclerosis; myeloperoxidase

Mesh:

Substances:

Year:  2014        PMID: 24407029      PMCID: PMC3966977          DOI: 10.1161/ATVBAHA.113.303044

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  48 in total

1.  Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques.

Authors:  Jonathan E Feig; Sajesh Parathath; James X Rong; Stephanie L Mick; Yuliya Vengrenyuk; Lisa Grauer; Stephen G Young; Edward A Fisher
Journal:  Circulation       Date:  2011-02-21       Impact factor: 29.690

2.  Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis.

Authors:  Katey J Rayner; Frederick J Sheedy; Christine C Esau; Farah N Hussain; Ryan E Temel; Saj Parathath; Janine M van Gils; Alistair J Rayner; Aaron N Chang; Yajaira Suarez; Carlos Fernandez-Hernando; Edward A Fisher; Kathryn J Moore
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

Review 3.  Why targeting HDL should work as a therapeutic tool, but has not.

Authors:  Mary G Sorci-Thomas; Michael J Thomas
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

Review 4.  Preclinical mouse models and methods for the discovery of the causes and treatments of atherosclerosis.

Authors:  Bernd Hewing; Edward A Fisher
Journal:  Expert Opin Drug Discov       Date:  2012-02-10       Impact factor: 6.098

5.  High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo.

Authors:  Christina A Bursill; Maria L Castro; Douglas T Beattie; Shirley Nakhla; Emiel van der Vorst; Alison K Heather; Philip J Barter; Kerry-Anne Rye
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08-11       Impact factor: 8.311

6.  Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages.

Authors:  Lemin Zheng; Megan Settle; Gregory Brubaker; Dave Schmitt; Stanley L Hazen; Jonathan D Smith; Michael Kinter
Journal:  J Biol Chem       Date:  2004-10-21       Impact factor: 5.157

7.  Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging.

Authors:  Cinzia Parolini; Marta Marchesi; Paolo Lorenzon; Mauro Castano; Elena Balconi; Luigi Miragoli; Linda Chaabane; Alberto Morisetti; Vito Lorusso; Bradley J Martin; Charles L Bisgaier; Brian Krause; Roger S Newton; Cesare R Sirtori; Giulia Chiesa
Journal:  J Am Coll Cardiol       Date:  2008-03-18       Impact factor: 24.094

8.  Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice.

Authors:  Eugene Trogan; Jonathan E Feig; Snjezana Dogan; George H Rothblat; Véronique Angeli; Frank Tacke; Gwendalyn J Randolph; Edward A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-01       Impact factor: 11.205

9.  Rapid regression of atherosclerosis with MTP inhibitor treatment.

Authors:  Bernd Hewing; Saj Parathath; Christina K Mai; M Isabel Fiel; Liang Guo; Edward A Fisher
Journal:  Atherosclerosis       Date:  2013-01-01       Impact factor: 5.162

10.  Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle.

Authors:  Arundhati Undurti; Ying Huang; Joseph A Lupica; Jonathan D Smith; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

View more
  60 in total

1.  Urinary apolipoprotein AI in children with kidney disease.

Authors:  Amanda J Clark; Kathy Jabs; Tracy E Hunley; Deborah P Jones; Rene G VanDeVoorde; Carl Anderson; Liping Du; Jianyong Zhong; Agnes B Fogo; Haichun Yang; Valentina Kon
Journal:  Pediatr Nephrol       Date:  2019-06-23       Impact factor: 3.714

Review 2.  Atherosclerosis: Making a U Turn.

Authors:  Ira J Goldberg; Gaurav Sharma; Edward A Fisher
Journal:  Annu Rev Med       Date:  2020-01-27       Impact factor: 13.739

3.  Methionine oxidized apolipoprotein A-I at the crossroads of HDL biogenesis and amyloid formation.

Authors:  Andrzej Witkowski; Gary K L Chan; Jennifer C Boatz; Nancy J Li; Ayuka P Inoue; Jaclyn C Wong; Patrick C A van der Wel; Giorgio Cavigiolio
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

Review 4.  LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?

Authors:  Bernd Hewing; Ulf Landmesser
Journal:  Curr Cardiol Rep       Date:  2015-07       Impact factor: 2.931

5.  Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation.

Authors:  Tessa J Barrett; Emilie Distel; Andrew J Murphy; Jiyuan Hu; Michael S Garshick; Yoscar Ogando; Jianhua Liu; Tomas Vaisar; Jay W Heinecke; Jeffrey S Berger; Ira J Goldberg; Edward A Fisher
Journal:  Circulation       Date:  2019-09-30       Impact factor: 29.690

6.  Oxidized high density lipoprotein induces macrophage apoptosis via toll-like receptor 4-dependent CHOP pathway.

Authors:  Shutong Yao; Hua Tian; Li Zhao; Jinguo Li; Libo Yang; Feng Yue; Yanyan Li; Peng Jiao; Nana Yang; Yiwei Wang; Xiangjian Zhang; Shucun Qin
Journal:  J Lipid Res       Date:  2016-11-28       Impact factor: 5.922

7.  Alterations of Cholesterol Metabolism in Inflammation-Induced Atherogenesis.

Authors:  David P Hajjar; Katherine A Hajjar
Journal:  J Enzymol Metab       Date:  2016-05-31

8.  Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.

Authors:  Joseph A DiDonato; Kulwant Aulak; Ying Huang; Matthew Wagner; Gary Gerstenecker; Celalettin Topbas; Valentin Gogonea; Anthony J DiDonato; W H Wilson Tang; Ryan A Mehl; Paul L Fox; Edward F Plow; Jonathan D Smith; Edward A Fisher; Stanley L Hazen
Journal:  J Biol Chem       Date:  2014-02-20       Impact factor: 5.157

9.  Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis.

Authors:  Maryam Zamanian-Daryoush; Valentin Gogonea; Anthony J DiDonato; Jennifer A Buffa; Ibrahim Choucair; Bruce S Levison; Randall A Hughes; Andrew D Ellington; Ying Huang; Xinmin S Li; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2020-02-25       Impact factor: 5.157

Review 10.  Dysfunctional HDL and atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Nat Rev Cardiol       Date:  2015-09-01       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.